Thierry Hercend, Chairman of the Supervisory Board.
A medical doctor with a PhD in immunology, Thierry has acquired more than 30 years of experience in the academic sector and the pharmaceutical industry in various therapeutic fields, including oncology and inflammatory diseases. Since 2006, Thierry has been Venture Partner at Edmond de Rothschild Investment Partners (EdRIP). From 2002 to 2005, Thierry was Vice President in charge of the therapeutic oncology sector for Aventis. From 1998 to 2002, Thierry was Vice President (Europe) for research at Vertex Pharmaceuticals. He entered the pharmaceutical industry in 1990 at Roussel-Uclaf as Director of Therapeutic Immunology and then Scientific Director of the Health Division.
Before joining the industrial sector, Thierry was a department head, responsible for the Immuno-Hematology laboratory at Gustave Roussy Villejuif Institute, France, and director of the INSERM U333 unit dedicated to the immunology of tumors and professor of immunology at Université de Médecine-Paris XI, France.
Thierry is the author of more than 120 publications in oncology, autoimmune diseases and transplantation.
Gerald Möller (independent member), Vice Chairman of the Supervisory Board.
Gerald, a Doctor of Science, has acquired more than 30 years of experience in the pharmaceutical and diagnostics industry. Since 2002, he is investment advisor at HBM Partners in Switzerland. He is also chairman of the supervisory boards of several companies in the health sector, such as 4Sigma Ltd, Definiens AG, Invendo-Medical GmbH and MorphoSys AG, and board member at FIND Foundation, Illumina Inc. and Adrenomed AG.
From 1975 to 1998, Gerald held management positions in Germany, Japan, the United States and the Netherlands for Boehringer Mannheim Group. In 1995, he became Chief Executive Officer of Boehringer Mannheim Group, the sales of which exceeded US$4 billion in 1997. Following the sale of Boehringer Mannheim Group to Roche in 1998, Gerald was appointed Head of Global Development and Strategic Marketing Pharmaceuticals as well as a member of Roche's Executive Committee. Gerald left Roche in December 1998.
Gerald obtained his doctorate in science at the University of Kiel in Germany in 1975.
Raphaël Wisniewski, permanent representative of Edmond de Rothschild Investment Partners, member of the Supervisory Board.
Raphaël joined the life sciences team at Edmond de Rothschild Investment Partners in 2001 where he participated in more than 20 investments in European or American companies in biotechnology, medical technologies and molecular diagnosis. Prior to that, he worked in London in the Healthcare Corporate Finance division at Salomon Smith Barney and Goldman Sachs and in the financial department of private British clinics of Générale de Santé Group.
Raphaël graduated from HEC in France and has a Economics and Finance degree from Institut d'Etudes Politiques, Paris. Raphaël sits on the boards of directors of EOS Imaging, Implanet, Genticel, Poxel, Cellnovo and Regado Biosciences.
Olivier Martinez, permanent representative of Bpifrance Investissement, member of the Supervisory Board.
From 1992 to 1997, Olivier was student-researcher at the Pasteur Institute then at the Curie Institute in France in the field of cell biology.
In 1998, after management training, Olivier joined the life sciences department at Gemini Consulting where he spent two years working on pharmaceutical and health sector products.
In 2000, Olivier joined Bioam Gestion as an account executive and was appointed Investment Director and member of the Management Board in 2004. Following the absorption of Bioam Gestion by CDC Enterprises in July 2010, Olivier joined the life sciences team at CDC Enterprises, which manages the InnoBio and Bioam Funds and advises the Investment Strategy Fund (FSI) on its investments in biotechnology companies. CDC Enterprises, the FSI, FSI Regions and OSEO are now grouped within Bpifrance, the public investment bank.
Olivier is an alumnus of the Ecole Normale Supérieure (Ulm), and obtained a doctorate in Cell Biology at the University of Paris XI in 1997, as well as a degree from the College of Engineers in 1998.
Didier Hoch, independent member of the Supervisory Board.
Didier has acquired more than 25 years of experience in the pharmaceutical industry. For nearly ten years, he was President of Sanofi-Pasteur–MSD, the joint venture of Sanofi-Aventis and Merck & Co for vaccines. Sanofi-Pasteur–MSD launched Gardasil® on the European market, a preventive vaccine against HPV, which has been very successful.
Before taking on the role of President of Sanofi-Pasteur MSD from 2000 to 2010, Didier was Vice President Africa and Middle East of Aventis Pharma International. Prior to that, he was Deputy Chief Executive Officer of Rhône-Poulenc Rorer France and from 2003 to 2009 was President of the Association of European Vaccine Manufacturers (EVM). He was also President of Pevion in Switzerland until 2013.
He is currently an independent member of the management of DBV Technologies and Effimune (France).
Didier obtained an MD degree at the University of Lyon in 1984.
Rainer Strohmenger, member of the Supervisory Board, permanent representative of Wellington Partners.
With more than 20 investments in start-up companies, Rainer is one of the most experienced risk-capital investors in Europe in the life sciences sector. He joined Wellington Partners in 1997 and became a partner in December 2000. His 16 years of investment activities covered the financing of some of the greatest European successes in Biotechnology, Medical Technologies and Diagnostics companies.
Prior to joining Wellington Partners, Rainer was a medical researcher in cardiovascular physiology, and also worked in health economics at Ludwig Maximilian University in Munich.
Rainer obtained an MD degree as well as a Master of Economics at Ludwig Maximilian University, Munich.
Mary Tanner, independent member of the Supervisory Board.
Mary is co-founder and Senior Managing Director at the consultancy firm Evolution Life Sciences Partners LLC, specializing in strategic and financial advice for companies operating in the life sciences and health care. Based in New York, Mary has held various positions at world-class investment banks such as Lehman Brothers Inc, Bear Stearns & Co, and Peter J Solomon. Mary has over 25 years of experience in health-related industries. She has developed strong expertise in the pharmaceutical, biotechnology, diagnostic, medical devices, and healthcare sectors.
She is a member of the board of directors of Lineagen Inc, a molecular diagnostics company, and sits on the Board of Deans of Yale School of Medicine and on the Advisory Board of Yale School of Management.
Mary received a B.A. from Harvard University. An American native, she is also fluent in French.
Caroline Laplane, member of the Supervisory Board.
Caroline is a board member of LBP S.A., a Belgium private investment holding company, as well as board member of two agrifood companies in France. LPB SA has supported the Company throughout several financing rounds since its inception in 2001.
Caroline holds a doctorate in Pharmaceutical Sciences from Paul Sabatier University, Toulouse, France since 1994 where she also obtained a Masters in pharmaceutical industry management and marketing. Until 2000, she held several international senior marketing management positions at Pierre Fabre Laboratories, in the Oncology business unit specialized in lung and breast cancers (Navelbine®).
|Supervisory Board Internal Regulations||Download|